Satoshi Tamada
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: December 19, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Journal: Nature medicine
Published: January 22, 2025
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Journal: European urology
Published: December 09, 2023
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Journal: Japanese journal of clinical oncology
Published: November 08, 2023
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Journal: European urology
Published: September 04, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Journal: European urology
Published: January 17, 2023
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Journal: International journal of clinical oncology
Published: September 19, 2022
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Journal: International journal of clinical oncology
Published: June 22, 2022
Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma.
Journal: International cancer conference journal
Published: February 15, 2022
Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: January 28, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Journal: European urology
Published: December 03, 2021
Last Updated: 09/26/2026